{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:53:45Z","timestamp":1791892425790,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Huazhong University of Science and Technology Tongji Medical College Tongji Hospital","doi-asserted-by":"publisher","award":["2025A21"],"award-info":[{"award-number":["2025A21"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2025-18-49"],"award-info":[{"award-number":["320.6750.2025-18-49"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108338","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:00:19Z","timestamp":1791356419000},"page":"108338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Approval-standardized postmarketing safety reporting phenotypes of talquetamab versus BCMA-directed bispecific antibodies in multiple myeloma"],"prefix":"10.1016","volume":"171","author":[{"given":"He","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-6021","authenticated-orcid":false,"given":"Wenxi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2026.108338_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2026.108338_bib2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.leukres.2026.108338_bib3","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.leukres.2026.108338_bib7","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108338_bib8","unstructured":"U.S. Food and Drug Administration. TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use: highlights of prescribing information. Revised October 2022. Accessed August 10, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf."},{"key":"10.1016\/j.leukres.2026.108338_bib9","unstructured":"U.S. Food and Drug Administration. ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use: highlights of prescribing information. Revised August 2023. Accessed August 10, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf."},{"key":"10.1016\/j.leukres.2026.108338_bib10","unstructured":"U.S. Food and Drug Administration. TALVEY (talquetamab-tgvs) injection, for subcutaneous use: highlights of prescribing information. Revised August 2023. Accessed August 10, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"issue":"10","key":"10.1016\/j.leukres.2026.108338_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib13","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2026.0001","article-title":"Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Kumar","year":"2026","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.leukres.2026.108338_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04522-3","article-title":"FcRH5\u00d7CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial","author":"Cohen","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2026.108338_bib16","unstructured":"U.S. Food and Drug Administration. FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma. March 5, 2026. Accessed September 24, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple."},{"issue":"5","key":"10.1016\/j.leukres.2026.108338_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2603870","article-title":"Teclistamab in multiple myeloma with one to three previous lines of therapy","volume":"395","author":"Touzeau","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2026.108338_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2604657","article-title":"Talquetamab-daratumumab in relapsed or refractory Myeloma","volume":"395","author":"Mina","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108338_bib19","unstructured":"U.S. Food and Drug Administration. Ongoing Cancer Accelerated Approvals. Accessed September 24, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ongoing-cancer-accelerated-approvals."},{"key":"10.1016\/j.leukres.2026.108338_bib20","article-title":"The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma","volume":"12","author":"Zhou","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"issue":"7","key":"10.1016\/j.leukres.2026.108338_bib21","article-title":"Neurologic adverse events associated with T-cell engager therapy in multiple myeloma: a pharmacovigilance study","volume":"17","author":"Khan","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-025-01334-5","article-title":"Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma","volume":"15","author":"Golmohammadi","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108338_bib23","doi-asserted-by":"crossref","unstructured":"Shen S., Zhao W., Gao Z., Yang Z. Clinical reporting phenotypes of haematological CD3 T-cell-engaging bispecific antibodies: a FAERS pharmacovigilance study with JADER external validation. Preprint. Posted July 15, 2026. SSRN. doi:10.2139\/ssrn.7117992.","DOI":"10.2139\/ssrn.7117992"},{"key":"10.1016\/j.leukres.2026.108338_bib24","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). Accessed August 10, 2026. https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers."},{"issue":"2","key":"10.1016\/j.leukres.2026.108338_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"2","key":"10.1016\/j.leukres.2026.108338_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug. Saf."},{"issue":"1","key":"10.1016\/j.leukres.2026.108338_bib27","first-page":"20","article-title":"Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab","volume":"32","author":"Laheij","year":"2024","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.leukres.2026.108338_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-026-07110-0","article-title":"Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients","author":"Albrecht","year":"2026","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108338_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-026-07026-9","article-title":"Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis","volume":"105","author":"Spataro","year":"2026","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108338_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.leukres.2026.108338_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1722579","article-title":"TS. To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies","volume":"16","author":"Paulsen","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2026.108338_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1573353","article-title":"Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUS-PV guideline and a call to action","volume":"16","author":"Hammad","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.leukres.2026.108338_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00077","article-title":"Prognostic factors influencing the efficacy and safety of teclistamab and elranatamab in multiple myeloma: a multicenter propensity-weighted analysis","volume":"3","author":"Zerbit","year":"2026","journal-title":"JCO Oncol. Adv."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:59:34Z","timestamp":1791889174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S0145212626001827"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108338","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approval-standardized postmarketing safety reporting phenotypes of talquetamab versus BCMA-directed bispecific antibodies in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108338"}}